

# WEIGHT LOSS





## Weight Loss Medication Recommendation

Weight loss medications can be a valuable tool for individuals who are struggling to achieve healthy and sustainable weight reduction.



Currently, a variety of weight loss medications are available on the market, with each having its own mechanism of action. Due to the various mechanisms of obesity and depending on your genetic profile, some medications may be more suitable for you than others. The benefit of the **Scylex Weight Loss panel** is that we test genes shown to have implications in the different classes of weight loss medications (*refer to our info page on this panel*).



This, in effect, gives you a personalized recommendation as to which weight loss medications would be most effective for your weight loss journey.

## Test Results

The list of medications and your recommendations based on your genetic profile are below:

(Example<sup>®</sup>, Trulicity<sup>®</sup>, Wegovy<sup>®</sup>, Victoza<sup>®</sup>, Mounjaro<sup>®</sup>, Contrave<sup>®</sup>)

BEST MEDICATION	MODERATELY BEST MEDICATION	LAST MEDICATION
<p>Example<sup>®</sup> Mounjaro<sup>®</sup></p>	<p>Contrave<sup>®</sup></p>	<p>Trulicity<sup>®</sup> Wegovy<sup>®</sup> Victoza<sup>®</sup></p>

## Results Summary

Drug	Gene of Interest	SNP ID	Genotype Result	Explanation of Recommendation
<b>Stimulant Tobacco Nicotine</b>	SNP-10	rs4822761	rs4822761 positive	rs4822761 positive variants have a decreased response to bupropion
	SNP-11			
<b>Carbinoxamine</b>	SNP-12/13/14	rs1800487	A/A	A/A + GG genotype may have an increased weight loss response to bupropion/nicotine as compared to patients with the GG genotype
<b>Vitamin</b>	SNP-15	rs4822761	A/A	Genotypes A/A + GG are associated with increased response to bupropion
<b>MC4R</b>	PCMC		Not Tested	
	MC4R	rs499693	A/C	This defect in the MC4R signaling pathway for appetite. Will benefit from MC4R agonist replacement therapy for weight loss
	MC4R	rs7792293	C/C	This defect in the MC4R signaling pathway for appetite. Will benefit from MC4R agonist replacement therapy for weight loss
	UP	rs7794028	G/G	This defect in the MC4R signaling pathway for appetite. Will benefit from MC4R agonist replacement therapy for weight loss
	UPB	rs13761	A/A	
	UPB	rs1807098	C/T	This defect in the MC4R signaling pathway for appetite. Will benefit from MC4R agonist replacement therapy for weight loss
	PCMC	rs4232	G/G	This defect in the MC4R signaling pathway for appetite. Will benefit from MC4R agonist replacement therapy for weight loss